Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24037975 | 0.80 | — | — | |
| SCHEMBL21451349 | 0.78 | CA2 (0.35) | ALDH1A1KDM4ESMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL15417760 | 0.74 | PDXK (0.39) | PDXKLMNAALDH1A1KDM4EHPGD | |
| SCHEMBL14586463 | 0.73 | CYP11B1 (0.40) | LMNAALDH1A1 | |
| SCHEMBL29316522 | 0.72 | ALDH1A1 (0.42) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL13403322 | 0.72 | PDXK (0.42) | PDXKLMNAALDH1A1KDM4EHPGD | |
| SCHEMBL17553885 | 0.72 | PDXK (0.38) | PDXKLMNAALDH1A1KDM4EHPGD | |
| SCHEMBL12341056 | 0.72 | ALOX5 (0.36) | LMNAALDH1A1HPGDCA2TP53 | |
| SCHEMBL11955173 | 0.72 | GABRA1 (0.32) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19CA2 | |
| SCHEMBL20887505 | 0.71 | PDXK (0.37) | PDXKLMNAALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2020-06-02 | — | — | US | disclosed |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | PDXK 1011/4885LMNA 2738/4885ALDH1A1 2101/4885 |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | PDXK 1011/4885LMNA 2738/4885ALDH1A1 2101/4885 |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | PDXK 592/4885LMNA 1809/4885ALDH1A1 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.